Pirfenidone-induced hyponatraemia: insight in mechanism, risk factor and management

Pirfenidone was approved in October 2014 in the USA for the treatment of idiopathic pulmonary fibrosis. Although not included in the adverse events published in the CAPACITY-1 and CAPACITY-2 or ASCEND trials, hyponatraemia was reported in supplementary data with rate of 3.4% in the active therapy ar...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:BMJ Case Rep
Hlavní autoři: Silhan, Leann, Galiatsatos, Panagis, Corwine, Justine, Danoff, Sonye
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Publishing Group 2017
Témata:
Unexpected Outcome (Positive or Negative) Including Adverse Drug Reactions
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720250/
https://ncbi.nlm.nih.gov/pubmed/29183898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2017-222734
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky